ARIES 144 week results: Durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine

HIV Clinical Trials

Volumn 13, Issue 5, 2012, Pages 233-244

  Squires, Kathleen E ^a   Young, Benjamin ^b   Dejesus, Edwin ^c   Bellos, Nicholaos ^d   Murphy, Daniel ^e   Ward, Douglas ^f   Zhao, Henry H ^g   Ross, Lisa L ^g   Shaefer, Mark S ^h  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d Southwest Infectious Disease Associates   (United States)

^e Clinique Medicale l'Actuel   (Canada)

^f Dupont Circle Physician's Group   (United States)

^g GLAXOSMITHKLINE   (United States)

^h VIIV HEALTHCARE   (United States)

Author keywords

abacavir; antiretroviral therapy; atazanavir; lamivudine; ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; BILIRUBIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; YOUNG ADULT;

EID: 84868678578     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1305-233     Document Type: Article

References (23)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. October 14, 2011; 1-167. http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed October 27, 2011.
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA. 2010; 304: 321-333.
3. European AIDS Clinical Society Guidelines. Version 6.0. October 2011; 1-156. www.europeanaidsclinicalsociety. org. Accessed on October 27, 2011.
4. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov. 2003;2: 624-634. (Pubitemid 37361766)
5. Becker S. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs. 2003;12(3): 410-412.
6. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13: 2083-2089. (Pubitemid 29509585)
7. Samaras K, Richardson R, Carr A. Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults. AIDS. 2010; 24: 1727-1731.
8. Collot-Teixeira S, De Lorenzo F, et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther. 2009;85(4): 375-378.
9. Yilmaz S, Boffito M, Collot-Teixeira S, et al. Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays. Genomics. 2010;96(1): 57-65.
10. Squires KE, Young B, DeJesus E; ARIES Study Team. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010;11(2): 69-79.
11. Squires KE, Young B, Dejesus E; ARIES Study Team. Similar effi cacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24(13): 2019-2027.
12. HIV Drug Resistance Mutations. http://www.iasusa. org/resistance- mutations/index.html. December 2010. Accessed September 20, 2011
13. Levey AS, Bosch J P, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomeru-lar fi ltration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130: 461-470. (Pubitemid 29135798)
14. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285: 2486-2497. http://www.nhlbi. nih.gov/guidelines/cholesterol/atp3xsum. pdf.
15. Pavie J, Porcher R, Torti C, et al. Effi cacy and safety of a switch to unboosted atazanavir in combination with nucle-oside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother. 2011; 66: 2372-2378.
16. Ghosn J, Carosi G, Moreno S, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther. 2010;15(7): 993-1002.
17. Fux CA, Rauch A, Simcock M, et al Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in calculated glomerular fi ltration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12: 1165-1173.
18. Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular fi ltration rate by creatinine or cystatin C in naïve HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defi c Syndr. 2012;59(1): 18-30.
19. Mocroft A, Kirk O, Reiss P, et al; EuroSIDA Study Group. Estimated glomerular fi ltration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11): 1667-1678.
20. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: fi nal results. J Infect Dis. 2011; 204: 1191-1201.
21. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopi-navir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372: 646-655.
22. Elion R, DeJesus E, Sension M, et al. Once-daily aba-cavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48 week pilot study. HIV Clin Trials. 2008: 9(3): 152-163. (Pubitemid 351892869)
23. Truvada (Gilead BioSciences) label approved July 8, 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021752s027lbl.pdf. Accessed June 12, 2012.